SYNVACCINE
Desconocido
ARDAT: Accelerating Research Development for Advanced Therapies
SYNVACCINE LTD
participó en un
H2020:
H2020-JTI-IMI2-2019-18-two-stage
Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado
2020-11-11 - 2025-10-31 | Financiado
SynVaccine: Rational Design and Construction of Viral Based Products
SYNVACCINE LTD
tramitó un
H2020:
H2020-SMEInst-2016-2017
In order to be fully effective as an oncolytic virus or vaccine, achieving of precise and specific traits are pivotal. However, current tech...
2017-05-16 - 2017-09-30 | Financiado
2017-05-16 - 2017-09-30 | Financiado
* No se disponen de datos de la empresa actual.